Gout and Hyperuricemia: A Narrative Review of Their Comorbidities and Clinical Implications
Author Information
Author(s): Timsans Janis, Palomäki Antti, Kauppi Markku
Primary Institution: Department of Rheumatology, Päijät-Häme Central Hospital, Wellbeing Services County of Päijät-Häme, Lahti, Finland
Hypothesis
This review aimed to summarize the current knowledge on the risk factors and pathophysiological drivers of hyperuricemia and gout, examine the comorbidities linked to these conditions, and discuss the clinical implications for optimizing patient care.
Conclusion
Gout and hyperuricemia are increasingly prevalent metabolic conditions that require a holistic management approach due to their association with numerous comorbidities and elevated mortality risk.
Supporting Evidence
- Gout is the most common form of inflammatory arthritis, caused by the deposition of monosodium urate crystals in the joints due to elevated serum uric acid levels.
- Gout and hyperuricemia are recognized as systemic metabolic disorders associated with a range of comorbidities, including cardiovascular diseases and chronic kidney disease.
- Effective management of gout necessitates a comprehensive approach that considers underlying metabolic disturbances and comorbid conditions.
Takeaway
Gout is not just a painful joint problem; it can also lead to other serious health issues. Managing it well means looking after the whole body, not just the sore joints.
Methodology
This is a narrative review summarizing existing knowledge on gout and hyperuricemia, their risk factors, comorbidities, and clinical implications.
Limitations
The review is based on existing literature and may not include all recent studies or data.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website